CompletedPhase 1

A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in Smokers

United States109 participantsStarted 2010-04

Plain-language summary

A randomized, double-blind, active-controlled, crossover, pilot study to evaluate the safety and efficacy of CigRx™ Lozenge, a dietary supplement, in daily smokers in temporarily reducing the desire to smoke

Who can participate

Age range23 Years – 72 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Healthy adult smokers * Smoking for at least 5 years * Smoking at least one (1) pack of cigarettes a day Exclusion Criteria: * Allergy to lozenge components

What they're measuring

Effect on subject's craving to smoke

Timeframe: 4 hours

Trial details

NCT IDNCT01262170

SponsorRock Creek Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2010-04

View on ClinicalTrials.gov More Smoking trials